{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:39Z","timestamp":1791876939407,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"publisher","award":["2021.035.1"],"award-info":[{"award-number":["2021.035.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020132","name":"TU Dresden Faculty of Medicine Carl Gustav Carus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["318488004"],"award-info":[{"award-number":["318488004"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.08.013","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T03:06:56Z","timestamp":1755745616000},"page":"e1108-e1119.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Value of Multicolor-Flow Cytometric Measurable Residual Disease Detection in Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation: Potential Role of HLA-DR"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8213-2047","authenticated-orcid":false,"given":"Maximilian A.","family":"R\u00f6hnert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"L\u00f6ffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e","family":"Kunadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Moritz","family":"Middeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Thielecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1191-9448","authenticated-orcid":false,"given":"Friedemann","family":"Uschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingmar","family":"Glauche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Oelschl\u00e4gel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"von Bonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-9178","authenticated-orcid":false,"given":"Jonas","family":"Schadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2025.08.013_bib0001","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.08.013_bib0002","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.1985.3.12.1583","article-title":"Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group","volume":"3","author":"B\u00fcchner","year":"1985","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.08.013_bib0003","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.08.013_bib0004","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3 -internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2025.08.013_bib0005","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood.2021014520","article-title":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML","volume":"139","author":"Murdock","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.08.013_bib0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.clml.2025.08.013_bib0007","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.clml.2025.08.013_bib0008","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.clml.2025.08.013_bib0009","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.20.00475","article-title":"Immune biology of acute myeloid leukemia: implications for immunotherapy","volume":"39","author":"Khaldoyanidi","year":"2021","journal-title":"J Clin Oncol."},{"issue":"24","key":"10.1016\/j.clml.2025.08.013_bib0011","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2025.08.013_bib0012","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.clml.2025.08.013_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12071835","article-title":"HLA evolutionary divergence as a prognostic marker for AML patients undergoing allogeneic stem cell transplantation","volume":"12","author":"Roerden","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.clml.2025.08.013_bib0014","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.08.013_bib0015","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.4049\/jimmunol.140.5.1660","article-title":"Regulation of HLA-DR gene by IFN-gamma. Transcriptional and post-transcriptional control","volume":"140","author":"Rosa","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2025.08.013_bib0016","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.4049\/jimmunol.1500262","article-title":"Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion","volume":";195, (6),","author":"Khaznadar","year":"2015","journal-title":"J Immunol."},{"issue":"7","key":"10.1016\/j.clml.2025.08.013_bib0017","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1158\/0008-5472.CAN-10-3689","article-title":"Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells","volume":"71","author":"van Luijn","year":"2011","journal-title":"Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.08.013_bib0018","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-145801","article-title":"The impact of hypomethylating agents and BCL-2 inhibitor on HLA expression on THP-1 cells","volume":"138","author":"Peton","year":"2021","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2025.08.013_bib0019","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1182\/blood.2022017795","article-title":"Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells","volume":"141","author":"Rimando","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.08.013_bib0020","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1182\/blood-2022-157054","article-title":"Pilot trial of IFN-\u03b3 and donor lymphocyte infusion to treat relapsed AML and MDS after allogeneic hematopoietic stem cell transplantation","volume":"140","author":"Ito","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.08.013_bib0021","article-title":"Predicting time to relapse in acute myeloid leukemia through stochastic modeling of minimal residual disease based on clonality data","volume":"1","author":"Dinh","year":"2021","journal-title":"Comput Syst Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.08.013_bib0022","first-page":"528","article-title":"Transplant in AML with measurable residual disease: proceed or defer?","volume":"2022","author":"Craddock","year":"2022","journal-title":"Hematol U S"},{"issue":"11","key":"10.1016\/j.clml.2025.08.013_bib0023","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2025.08.013_bib0024","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.08.013_bib0025","first-page":"381","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leuk Off J Leuk Soc Am Leuk Res Fund UK"},{"issue":"9","key":"10.1016\/j.clml.2025.08.013_bib0026","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41375-022-01647-5","article-title":"Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia","volume":"36","author":"R\u00f6hnert","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2025.08.013_bib0027","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.08.013_bib0028","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.08.013_bib0029","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41408-021-00558-5","article-title":"Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia","volume":"11","author":"Rautenberg","year":"2021","journal-title":"Blood Cancer J"},{"issue":"26","key":"10.1016\/j.clml.2025.08.013_bib0030","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.013_bib0031","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":";29","author":"Armbruster","year":"2008","journal-title":"Clin Biochem Rev"},{"issue":"12","key":"10.1016\/j.clml.2025.08.013_bib0032","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.3324\/haematol.2021.279777","article-title":"Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial","volume":"107","author":"Buccisano","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2025.08.013_bib0034","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.08.013_bib0035","series-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Sureda","year":"2024"},{"issue":"16","key":"10.1016\/j.clml.2025.08.013_bib0036","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.08.013_bib0037","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.08.013_bib0038","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bjh.17347","article-title":"Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1 \u2010mutated acute myeloid leukaemia","volume":"192","author":"Loghavi","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.08.013_bib0039","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/ajcp\/aqac083","article-title":"Abnormal CD13\/HLA-DR expression pattern on myeloblasts predicts development of myeloid neoplasia in patients with clonal cytopenia of undetermined significance","volume":"158","author":"Jevremovic","year":"2022","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"10.1016\/j.clml.2025.08.013_bib0040","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"Gilleece","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.08.013_bib0041","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol."},{"issue":"7","key":"10.1016\/j.clml.2025.08.013_bib0042","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable (\u2019minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:49:35Z","timestamp":1778838575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025002903"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Value of Multicolor-Flow Cytometric Measurable Residual Disease Detection in Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation: Potential Role of HLA-DR","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}